Candriam Luxembourg S.c.a. buys $24,238,039 stake in BioMarin Pharmaceutical (BMRN)

BioMarin Pharmaceutical (BMRN) : Candriam Luxembourg S.c.a. scooped up 38,628 additional shares in BioMarin Pharmaceutical during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Jul 26, 2016. The investment management firm now holds a total of 247,100 shares of BioMarin Pharmaceutical which is valued at $24,238,039.BioMarin Pharmaceutical makes up approximately 0.61% of Candriam Luxembourg S.c.a.’s portfolio.

Other Hedge Funds, Including , Shell Asset Management Co boosted its stake in BMRN in the latest quarter, The investment management firm added 5,179 additional shares and now holds a total of 27,415 shares of BioMarin Pharmaceutical which is valued at $2,689,137. BioMarin Pharmaceutical makes up approx 0.06% of Shell Asset Management Co’s portfolio.Dnb Asset Management As boosted its stake in BMRN in the latest quarter, The investment management firm added 300 additional shares and now holds a total of 12,800 shares of BioMarin Pharmaceutical which is valued at $1,171,072. BioMarin Pharmaceutical makes up approx 0.02% of Dnb Asset Management As’s portfolio.Integrated Investment Consultants boosted its stake in BMRN in the latest quarter, The investment management firm added 121 additional shares and now holds a total of 734 shares of BioMarin Pharmaceutical which is valued at $58,617. BioMarin Pharmaceutical makes up approx 0.03% of Integrated Investment Consultants’s portfolio.

BioMarin Pharmaceutical opened for trading at $98.18 and hit $99.62 on the upside on Friday, eventually ending the session at $99.42, with a gain of 1.24% or 1.22 points. The heightened volatility saw the trading volume jump to 14,48,311 shares. Company has a market cap of $16,138 M.

On the company’s financial health, BioMarin Pharmaceutical reported $-0.53 EPS for the quarter, missing the analyst consensus estimate by $ -0.25 based on the information available during the earnings call on Apr 28, 2016. Analyst had a consensus of $-0.28. The company had revenue of $236.70 million for the quarter, compared to analysts expectations of $239.85 million. The company’s revenue was up 16.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.43 EPS.

BioMarin Pharmaceutical Inc. develops and commercializes pharmaceuticals for serious diseases and medical conditions. The Company’s product portfolio is comprised of five approved products and multiple clinical and pre-clinical product candidates. Its approved products are Vimizim (elosulfase alpha) Naglazyme (galsulfase) Kuvan (sapropterin dihydrochloride) Aldurazyme (laronidase) and Firdapse (amifampridine phosphate). Vimizim received marketing approval in the United States the European Union and subsequently in several other countries. Naglazyme received marketing approval in the United States the European Union and subsequently in other countries. Kuvan was granted marketing approval in the United States the European Union. Aldurazyme which was developed in collaboration with Genzyme Corporation (Genzyme) was approved for marketing in the United States the European Union and subsequently in other countries. Firdapse was approved by the European Medicines Agency (EMA).

Leave a Reply

BioMarin Pharmaceutical - Is it time to Sell?

Top Brokerage Firms are advising their investors on BioMarin Pharmaceutical. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.